Gougerot-Sjögren
Veille bibliograhique : Gougerot-Sjögren
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Theander E et al. Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 2015 Sep;67(9):2427-36 | Lire le résumé |
| Nocturne G et al. Rheumatoid Factor and Disease Activity. Are Independent Predictors of Lymphoma in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. avr 2016;68(4):977‑85. | Lire le résumé |
| Baer AN et al. Association of Anticentromere Antibodies. With More Severe Exocrine Glandular Dysfunction in Sjögren’s Syndrome: Analysis of the Sjögren’s. International Collaborative Clinical Alliance Cohort. Arthritis Care Res. oct 2016;68(10):1554‑9 | Lire le résumé |
| Bowman SJ et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1440–50. | Lire le résumé |
| Bootsma H et al. Editorial: Rituximab in the Treatment of Sjögren’s Syndrome: Is It the Right or Wrong Drug? Arthritis Rheumatol Hoboken NJ. 2017 Jul;69(7):1346–9. | Lire le résumé |
| Bodewes ILA, Gottenberg J-E, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial. Rheumatology [Internet]. 25 juin 2019 [cité 23 juill 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez242/5523045 | Lire le résumé |
| Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology [Internet]. 11 août 2020 [cité 27 août 2020] | Lire le résumé |
| Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology [Internet]. 11 mai 2021 [cité 28 mai 2021]; | Lire le résumé |
| Duret PM, Schleiss C, Kawka L, Meyer N, Ye T, Saraux A, et al. Bruton’s tyrosine kinase (BTK) gene overexpression is associated with risk of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol Hoboken NJ. 28 avr 2023 | Lire le résumé |
| Xu D, Fang J, Zhang S, Huang C, Huang C, Qin L, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatol Oxf Engl. 3 juill 2023;kead265 | Lire le résumé |
| Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome. JCI Insight. 8 déc 2022;7(23):e163030. | Lire le résumé |
| De Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N, et al. Pregnancy outcomes in women with primary Sjögren’s syndrome: an analysis of data from the multicentre, prospective, GR2 study. Lancet Rheumatol. juin 2023;5(6):e330‑40. | Lire le résumé |
| Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 6 nov 2023;ard-2023-224691. | Lire le résumé |
| Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, et al. Combined anti‐Ro52/TRIM21 and anti‐Ro60/SSA antibodies are associated with increased Sjögren’s disease severity through interferon pathway activation. Arthritis Rheumatol. 21 déc 2023;art.42789. | Lire le résumé |
| Seror R, Chiche L, Beydon M, Desjeux G, Zhuo J, Vannier-Moreau V, et al. Estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study. RMD Open. févr 2024;10(1):e003591 | Lire le résumé |
| Xiong F, Pula D, Akpek EK, Bunya VY, Shiboski CH, Lietman TL, et al. Sjögren’s Versus Non-Sjögren’s Ocular Features: Similar Symptoms, But Significantly Worse Signs. Investig Opthalmology Vis Sci. 9 janv 2024;65(1):23 | Lire le résumé |
| Nguyen Y, Nocturne G, Henry J, Ng WF, Belkhir R, Desmoulins F, et al. Identification of distinct subgroups of Sjögren’s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. avr 2024;6(4):e216‑25 | Lire le résumé |
| Parker M, Zheng Z, Lasarev M, Alexandridis RA, Newton MA, Shelef MA, et al. Novel autoantibodies help diagnose anti-SSA antibody negative Sjögren’s disease and predict abnormal labial salivary gland pathology. medRxiv. 29 août 2023;2023.08.29.23294775 | Lire le résumé |
| Fisher BA, Szanto A, Ng WF, Bombardieri M, Posch MG, Papas AS, et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. mars 2020;2(3):e142‑52. | Lire le résumé |
| Mauro D, Pontarini E, Wehr P, Guggino G, Tang Y, et al. CD8+ tissue-resident memory T cells are expanded in primary Sjögren’s disease and can be therapeutically targeted by CD103 blockade. Ann Rheum Dis. 22 mai 2024;ard-2023-225069. | Lire le résumé |
| Fisher BA, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng WF, et al. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren’s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet. 31 juill 2024;S0140-6736(24)01211-X. | Lire le résumé |